SCHEDULE 13G/A: Eventide Asset Management Discloses 5.43% Stake in Mirum Pharmaceuticals

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a beneficial ownership of 5.43% in Mirum Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John collectively reported beneficial ownership of 2,606,938 shares of Mirum Pharmaceuticals, Inc. Common Stock.
• This aggregate ownership represents 5.43% of Mirum Pharmaceuticals, Inc.'s outstanding Common Stock as of December 31, 2024.
• Eventide Asset Management, LLC, a Delaware-based investment adviser, holds sole voting and dispositive power over all 2,606,938 shares.
• Finny Kuruvilla, M.D., Ph.D., and Robin C. John, both U.S. citizens, share voting and dispositive power over the same 2,606,938 shares.
• The shares are held by Eventide Asset Management, LLC as investment adviser to various funds and accounts, including Eventide Gilead Fund (1,430,349 shares or 2.98%), Eventide Healthcare & Life Sciences Fund (1,166,914 shares or 2.43%), and Eventide's separately managed accounts (9,675 shares or 0.02%).
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake by Eventide Asset Management in Mirum Pharmaceuticals is generally viewed positively as it indicates confidence from a professional investment firm, though it is a factual reporting document rather than a strategic announcement.

Positives

• The disclosure of a significant institutional stake (over 5%) by Eventide Asset Management indicates confidence from a professional investment firm in Mirum Pharmaceuticals, Inc.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a publicly traded pharmaceutical company. It reflects an investment decision by Eventide Asset Management within the healthcare and life sciences sector.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be perceived as a positive signal, potentially influencing investor confidence and stock valuation.

Key Dates

Keywords

Mirum Pharmaceuticals, Eventide Asset Management, Schedule 13G, beneficial ownership, institutional investment, common stock, MRUM